MRSN
Mersana Therapeutics Inc
$
27.300
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
27.6799
Open
27.450
VWAP
27.40
Vol
117.27K
Mkt Cap
136.47M
Low
27.220
Amount
3.21M
EV/EBITDA(TTM)
--
Total Shares
122.36M
EV
80.07M
EV/OCF(TTM)
--
P/S(TTM)
4.09
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
3.28M
+7.17%
-3.350
-31.21%
3.28M
+18.92%
-4.053
-14.67%
4.73M
-71.07%
-3.023
+9.94%
Estimates Revision
The market is revising No Change the revenue expectations for Mersana Therapeutics, Inc. (MRSN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 252.26%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+252.26%
In Past 3 Month
5 Analyst Rating
Wall Street analysts forecast MRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRSN is 34.92 USD with a low forecast of 30.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 27.300
Low
30.00
Averages
34.92
High
44.00
Current: 27.300
Low
30.00
Averages
34.92
High
44.00
Wedbush
Outperform
to
Neutral
downgrade
$55.25
2025-11-13
Reason
Wedbush
Price Target
$55.25
2025-11-13
downgrade
Outperform
to
Neutral
Reason
Wedbush downgraded Mersana Therapeutics (MRSN) to Neutral from Outperform after Day One Biopharmaceuticals (DAWN) agreed to acquire Mersana for total consideration of up to $55.25 per share in cash.
BTIG
Buy -> Neutral
downgrade
$25
2025-11-13
Reason
BTIG
Price Target
$25
2025-11-13
downgrade
Buy -> Neutral
Reason
BTIG downgraded Mersana Therapeutics (MRSN) to Neutral from Buy following news this morning of Mersana's acquisition by Day One Biopharmaceuticals (DAWN) for $25 per share in cash at closing plus one non-tradable CVR per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash.
Truist
Buy
to
Hold
downgrade
$36
2025-11-13
Reason
Truist
Price Target
$36
2025-11-13
downgrade
Buy
to
Hold
Reason
Truist downgraded Mersana Therapeutics (MRSN) to Hold from Buy with a price target of $30.75, down from $36, after Day One Biopharmaceuticals (DAWN) agreed to acquire Mersana for $25.00 per share in cash plus up to $30.25 per share in contingent value rights tied to clinical, regulatory, commercial, and collaboration milestones related to Emi-Le. The firm, which believes the deal will go through, thinks the CVR is worth $5.75.
Leerink
Jonathan Chang
Outperform -> Market Perform
downgrade
$29
2025-11-13
Reason
Leerink
Jonathan Chang
Price Target
$29
2025-11-13
downgrade
Outperform -> Market Perform
Reason
Leerink analyst Jonathan Chang downgraded Mersana Therapeutics (MRSN) to Market Perform from Outperform with a $29 price target after Day One Biopharmaceuticals (DAWN) agreed to buy the company for $25 per share in cash at closing plus one CVR worth up to an aggregate of $30.25 in cash.
LifeSci Capital
Charles Zhu
Outperform -> Market Perform
downgrade
$25
2025-11-13
Reason
LifeSci Capital
Charles Zhu
Price Target
$25
2025-11-13
downgrade
Outperform -> Market Perform
Reason
LifeSci Capital analyst Charles Zhu downgraded Mersana Therapeutics (MRSN) to Market Perform from Outperform after Day One Biopharmaceuticals (DAWN) agreed to buy the company for $25 per share in cash at closing plus one CVR worth up to an aggregate of $30.25 in cash.
Guggenheim
Michael Schmidt
Buy
to
Neutral
downgrade
$25
2025-11-13
Reason
Guggenheim
Michael Schmidt
Price Target
$25
2025-11-13
downgrade
Buy
to
Neutral
Reason
Guggenheim analyst Michael Schmidt downgraded Mersana Therapeutics (MRSN) to Neutral from Buy after Day One Biopharmaceuticals (DAWN) agreed to buy the company for $25 per share in cash at closing plus one CVR worth up to an aggregate of $30.25 in cash.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Mersana Therapeutics Inc (MRSN.O) is -2.00, compared to its 5-year average forward P/E of -3.58. For a more detailed relative valuation and DCF analysis to assess Mersana Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.58
Current PE
-2.00
Overvalued PE
-0.51
Undervalued PE
-6.65
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.11
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.66
Undervalued EV/EBITDA
-4.87
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2182.77
Current PS
0.00
Overvalued PS
11029.02
Undervalued PS
-6663.48
Financials
Annual
Quarterly
FY2025Q3
YoY :
-12.61%
11.01M
Total Revenue
FY2025Q3
YoY :
-38.06%
-7.48M
Operating Profit
FY2025Q3
YoY :
-34.40%
-7.55M
Net Income after Tax
FY2025Q3
YoY :
-35.47%
-1.51
EPS - Diluted
FY2025Q3
YoY :
-62.78%
-3.19M
Free Cash Flow
FY2025Q3
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q3
YoY :
-18.30%
-224.14
FCF Margin - %
FY2025Q3
YoY :
-24.93%
-68.53
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
15.5K
USD
2
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
51.3K
USD
18
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
6.7M
Volume
1
0-12
Months
9.1M
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
2
6.9M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
15.5K
USD
2
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
51.3K
USD
18
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MRSN News & Events
Events Timeline
2025-11-14 (ET)
2025-11-14
07:02:03
Mersana Therapeutics Announces Q3 Earnings Per Share of ($1.51), Below Consensus Estimate of 89 Cents
2025-11-13 (ET)
2025-11-13
10:08:45
Oppenheimer finds Day One's $285M investment in Mersana 'intriguing'
2025-11-13
06:03:28
Day One Biopharmaceuticals to purchase Mersana Therapeutics for a total of up to $285 million
Sign Up For More Events
Sign Up For More Events
News
7.0
11-17PRnewswireHalper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights
7.0
11-14PRnewswireHalper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights
8.5
11-14GlobenewswireBRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving Cidara Therapeutics, Mersana Therapeutics, TreeHouse Foods, and Gulf Island
Sign Up For More News
People Also Watch
CLSD
Clearside Biomedical Inc
2.720
USD
+4.21%
HYPR
Hyperfine Inc
1.050
USD
+2.44%
PMVP
PMV Pharmaceuticals Inc
1.320
USD
+0.76%
LSF
Laird Superfood Inc
2.580
USD
+4.03%
BNR
Burning Rock Biotech Ltd
14.250
USD
-8.26%
OPTX
Syntec Optics Holdings Inc
1.250
USD
-0.79%
FUSB
First US Bancshares Inc
13.850
USD
+0.80%
NSPR
InspireMD Inc
1.930
USD
+13.53%
VANI
Vivani Medical Inc
1.320
USD
-2.22%
FAQ
What is Mersana Therapeutics Inc (MRSN) stock price today?
The current price of MRSN is 27.3 USD — it has decreased -0.76 % in the last trading day.
What is Mersana Therapeutics Inc (MRSN)'s business?
What is the price predicton of MRSN Stock?
What is Mersana Therapeutics Inc (MRSN)'s revenue for the last quarter?
What is Mersana Therapeutics Inc (MRSN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Mersana Therapeutics Inc (MRSN)'s fundamentals?
How many employees does Mersana Therapeutics Inc (MRSN). have?